Maria Leonor Oliveira

List of Publications by Year
in descending order

37 papers	1,143 citations	430843 18 h-index	395678 33 g-index
38 all docs	38 docs citations	38 times ranked	1285 citing authors

#	Article	IF	Citations
1	Serum levels of anti-PspA and anti-PspC IgG decrease with age and do not correlate with susceptibility to experimental human pneumococcal colonization. PLoS ONE, 2021, 16, e0247056.	2.5	3
2	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines, 2021, 9, 1338.	4.4	17
3	Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A. PLoS ONE, 2020, 15, e0228055.	2.5	2
4	Efficacy of a Protein Vaccine and a Conjugate Vaccine Against Co-Colonization with Vaccine-Type and Non-Vaccine Type Pneumococci in Mice. Pathogens, 2020, 9, 278.	2.8	5
5	Systems analysis of subjects acutely infected with the Chikungunya virus. PLoS Pathogens, 2019, 15, e1007880.	4.7	33
6	Impaired expression of CXCL5 and matrix metalloproteinases in the lungs of mice with high susceptibility to Streptococcus pneumoniae infection. Immunity, Inflammation and Disease, 2018, 6, 128-142.	2.7	7
7	Mucosal immunization with PspA (Pneumococcal surface protein A)-adsorbed nanoparticles targeting the lungs for protection against pneumococcal infection. PLoS ONE, 2018, 13, e0191692.	2.5	40
8	Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae. PLoS ONE, 2017, 12, e0170157.	2.5	10
9	Evaluation of a Vaccine Formulation against Streptococcus pneumoniae Based on Choline-Binding Proteins. Vaccine Journal, 2015, 22, 213-220.	3.1	12
10	Aerobic exercise attenuates pulmonary inflammation induced byStreptococcus pneumoniae. Journal of Applied Physiology, 2014, 117, 998-1007.	2.5	29
11	Pertussis Toxin Improves Immune Responses to a Combined Pneumococcal Antigen and Leads to Enhanced Protection against Streptococcus pneumoniae. Vaccine Journal, 2014, 21, 972-981.	3.1	5
12	Mapping of Epitopes Recognized by Antibodies Induced by Immunization of Mice with PspA and PspC. Vaccine Journal, 2014, 21, 940-948.	3.1	22
13	Serotype-independent pneumococcal vaccines. Cellular and Molecular Life Sciences, 2013, 70, 3303-3326.	5.4	78
14	Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice. Vaccine, 2013, 31, 2465-2470.	3.8	5
15	Controlled Inflammatory Responses in the Lungs Are Associated with Protection Elicited by a Pneumococcal Surface Protein A-Based Vaccine against a Lethal Respiratory Challenge with Streptococcus pneumoniae in Mice. Vaccine Journal, 2012, 19, 1382-1392.	3.1	18
16	Cross-Reactivity of Antipneumococcal Surface Protein C (PspC) Antibodies with Different Strains and Evaluation of Inhibition of Human Complement Factor H and Secretory IgA Binding via PspC. Vaccine Journal, 2012, 19, 499-507.	3.1	17
17	Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae. Microbial Pathogenesis, 2012, 53, 243-249.	2.9	18
18	Lactic acid bacteria in the prevention of pneumococcal respiratory infection: Future opportunities and challenges. International Immunopharmacology, 2011, 11, 1633-1645.	3.8	75

#	Article	IF	Citations
19	Nasal immunization of mice withLactobacillus caseiexpressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice. FEMS Immunology and Medical Microbiology, 2011, 62, 263-272.	2.7	35
20	Economical Value of Vaccines for the Developing Countriesâ€"The Case of Instituto Butantan, a Public Institution in Brazil. PLoS Neglected Tropical Diseases, 2011, 5, e1300.	3.0	13
21	Generation of Polyclonal Antibodies Against Recombinant Human Glucocerebrosidase Produced in Escherichia coli. Molecular Biotechnology, 2010, 46, 279-286.	2.4	9
22	Combination of Pneumococcal Surface Protein A (PspA) with Whole Cell Pertussis Vaccine Increases Protection Against Pneumococcal Challenge in Mice. PLoS ONE, 2010, 5, e10863.	2.5	40
23	Immunization of Mice with Single PspA Fragments Induces Antibodies Capable of Mediating Complement Deposition on Different Pneumococcal Strains and Cross-Protection. Vaccine Journal, 2010, 17, 439-446.	3.1	77
24	Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microbial Pathogenesis, 2010, 48, 205-213.	2.9	35
25	Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains. Microbial Pathogenesis, 2009, 47, 157-163.	2.9	18
26	Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes and Infection, 2008, 10, 481-488.	1.9	52
27	Immunization of mice withLactobacillus caseiexpressing intimin fragments produces antibodies able to inhibit the adhesion of enteropathogenicEscherichia colito cultivated epithelial cells. FEMS Immunology and Medical Microbiology, 2008, 54, 245-254.	2.7	13
28	Optimized Immune Response Elicited by a DNA Vaccine Expressing Pneumococcal Surface Protein A Is Characterized by a Balanced Immunoglobulin G1 (IgG1)/IgG2a Ratio and Proinflammatory Cytokine Production. Vaccine Journal, 2008, 15, 499-505.	3.1	51
29	Intranasal vaccines for protection against resipratory and systemic bacterial infections. Expert Review of Vaccines, 2007, 6, 419-429.	4.4	29
30	Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes and Infection, 2006, 8, 1016-1024.	1.9	101
31	DNA vaccines expressing pneumococcal surface protein A (PspA) elicit protection levels comparable to recombinant protein. Journal of Medical Microbiology, 2006, 55, 375-378.	1.8	16
32	Production of Human Papillomavirus Type 16 L1 Virus-Like Particles by Recombinant Lactobacillus casei Cells. Applied and Environmental Microbiology, 2006, 72, 745-752.	3.1	72
33	Intradermal Immunization of Mice with Cholera Toxin B-Pneumococcal Surface Protein A Fusion Protein Is Protective against Intraperitoneal Challenge with Streptococcus pneumoniae. Infection and Immunity, 2005, 73, 3810-3813.	2.2	9
34	Antibodies produced against a fragment of filamentous haemagglutinin (FHA) ofBordetella pertussisare able to inhibit hemagglutination induced by the whole adhesin. FEMS Microbiology Letters, 2004, 240, 41-47.	1.8	6
35	Expression and characterization of cholera toxin Bâ€"pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice. Biochemical and Biophysical Research Communications, 2004, 321, 192-196.	2.1	57
36	Expression ofStreptococcus pneumoniaeantigens, PsaA (pneumococcal surface antigen A) and PspA (pneumococcal surface protein A) byLactobacillus casei. FEMS Microbiology Letters, 2003, 227, 25-31.	1.8	34

#	Article	IF	Citations
37	Molecular Cloning and Expression of a Functional Snake Venom Vascular Endothelium Growth Factor (VEGF) from theBothrops insularis Pit Viper. Journal of Biological Chemistry, 2001, 276, 39836-39842.	3.4	80